Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/II study of EMB-06 in relapsed or refractory multiple myeloma
CTR20212633Phase 2Terminated
- Sponsor
- EpimAb Biotherapeutics
- Start
- Feb 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cizutamig in multiple myeloma (MM), sponsored by EpimAb Biotherapeutics. Started Feb 2022; status: terminated.
02
Drugs
cizutamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20212633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212633.